Prof Deepu Madduri speaks to ecancer at the 2019 ASH meeting in Orlando about the findings from the CARTITUDE-1 study which evaluated the response rate of JNJ-4528, a BCMA-directed CAR T-cell therapy in patients with multiple myeloma.
She discusses the aim of the trial, which was to characterise safety and confirm the phase II dose.
Prof Madduri also describes the associated toxicities seen in these heavily pre-treated patients.
In terms of efficacy, she states that a 100 percent overall response rate was achieved and concludes by outlining the next steps for this study.
This program is funded in part via an independent grant from AbbVie. ecancer is editorially independent and there is no influence over content.
Watch the press conference here.
Read more about the study here.